Payment overview · 2025
General Payments
$759.43
48 reported records · 17 companies
Healthcare provider profile · identity verified
Chitra Raghavan, MD
Allopathic & Osteopathic Physicians|Internal Medicine · LEXINGTON, KY · NPI 1376603738
Verified facts
What the public records show
CMS Open Payments records show Chitra Raghavan, MD received $759.43 in general payments during 2025 across 48 reported records.
ABBVIE INC. accounted for 21.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Gemtesa, Jardiance, Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Vraylar by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 34 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 102 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 122 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Paxlovid by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported GEMTESA as an associated drug or biological on 61692 records involving 22152 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Gemtesa by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $164.00 | 21.6% | 12 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $157.36 | 20.7% | 12 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $58.56 | 7.7% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $51.39 | 6.8% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $48.80 | 6.4% | 3 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $44.90 | 5.9% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $34.93 | 4.6% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $32.40 | 4.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $31.76 | 4.2% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.96 | 2.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.60 | 2.3% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.46 | 2.3% | 1 | 2025 |
| Sage Therapeutics, LLC | Unresolved — no canonical attribution shown | $17.33 | 2.3% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $17.32 | 2.3% | 1 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $15.90 | 2.1% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $15.23 | 2.0% | 1 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $14.53 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $759.43 | 48 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $157.36 | 12 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $123.18 | 9 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $123.18 | 9 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $96.93 | 7 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $60.43 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $58.56 | 3 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $44.90 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $40.82 | 3 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $34.93 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $33.17 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $32.27 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $31.76 | 1 | 2025 |
Source payment records
|
|||||
| GIVLAARI Normalized: givlaari |
Drug | Alnylam Pharmaceuticals Inc. | $19.96 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.12 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.60 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.46 | 1 | 2025 |
Source payment records
|
|||||
| ZURZUVAE Normalized: zurzuvae |
Drug | Sage Therapeutics, LLC | $17.33 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $17.32 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $17.27 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| VAQTA Normalized: vaqta |
Biological | Merck Sharp & Dohme LLC | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $15.90 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $15.23 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.13 | 1 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $14.53 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 92 | exact normalized | Medicare Part D |
| GEMTESA gemtesa |
2025 | Gemtesa | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 102 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 41 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 34 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 13 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
90 | 24 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
34 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
102 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
41 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
122 | 25 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | GEMTESA open payments reported associated product |
CMS Open Payments — General Payments 61692 supporting records · 22152 recipient NPIs · example record 1176593503 |
Gemtesa · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 389 | 108 |
| Levothyroxine Sodium | Levothyroxine Sodium | 389 | 106 |
| Atorvastatin Calcium | Atorvastatin Calcium | 335 | 92 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 290 | 94 |
| Montelukast Sodium | Montelukast Sodium | 266 | 79 |
| Omeprazole | Omeprazole | 239 | 76 |
| Losartan Potassium | Losartan Potassium | 220 | 62 |
| Pravastatin Sodium | Pravastatin Sodium | 207 | 56 |
| Gabapentin | Gabapentin | 188 | 46 |
| Pantoprazole Sodium | Pantoprazole Sodium | 186 | 51 |
| Valsartan | Valsartan | 184 | 50 |
| Fluticasone Propionate | Fluticasone Propionate | 176 | 78 |
| Lisinopril | Lisinopril | 170 | 45 |
| Famotidine | Famotidine | 168 | 63 |
| Tizanidine Hcl | Tizanidine Hcl | 163 | 60 |
| Metoprolol Succinate | Metoprolol Succinate | 157 | 44 |
| Metformin Hcl Er | Metformin Hcl | 145 | 43 |
| Trazodone Hcl | Trazodone Hcl | 144 | 45 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 139 | 59 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 139 | 51 |
| Celecoxib | Celecoxib | 130 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 129 | 38 |
| Ozempic | Semaglutide | 122 | 25 |
| Diclofenac Sodium | Diclofenac Sodium | 116 | 49 |
| Azelastine Hcl | Azelastine Hcl | 114 | 63 |
| Sertraline Hcl | Sertraline Hcl | 109 | 29 |
| Jardiance | Empagliflozin | 102 | 23 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 101 | 27 |
| Simvastatin | Simvastatin | 101 | 28 |
| Tramadol Hcl | Tramadol Hcl | 101 | 30 |
| Meloxicam | Meloxicam | 100 | 42 |
| Hydrochlorothiazide | Hydrochlorothiazide | 97 | 30 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 95 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 93 | 30 |
| Eliquis | Apixaban | 92 | 23 |
| Synthroid | Levothyroxine Sodium | 90 | 24 |
| Potassium Chloride | Potassium Chloride | 87 | 33 |
| Ropinirole Hcl | Ropinirole Hcl | 87 | 23 |
| Glimepiride | Glimepiride | 85 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 80 | 25 |
| Bupropion Xl | Bupropion Hcl | 77 | 22 |
| Buspirone Hcl | Buspirone Hcl | 75 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 23 |
| Furosemide | Furosemide | 74 | 33 |
| Duloxetine Hcl | Duloxetine Hcl | 71 | 16 |
| Ezetimibe | Ezetimibe | 71 | 24 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 20 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 13 |
| Alendronate Sodium | Alendronate Sodium | 66 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 66 | 17 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 18 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 61 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 61 | 17 |
| Methylprednisolone | Methylprednisolone | 60 | 50 |
| Prednisone | Prednisone | 60 | 49 |
| Pioglitazone Hcl | Pioglitazone Hcl | 59 | 17 |
| Quetiapine Fumarate | Quetiapine Fumarate | 59 | 17 |
| Topiramate | Topiramate | 59 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 58 | 11 |
| Chlorthalidone | Chlorthalidone | 57 | 11 |
| Donepezil Hcl | Donepezil Hcl | 57 | 14 |
| Linzess | Linaclotide | 57 | 13 |
| Nystatin | Nystatin | 57 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 22 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 57 | 16 |
| Ondansetron Odt | Ondansetron | 55 | 25 |
| Allopurinol | Allopurinol | 53 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 53 | 40 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 52 | 12 |
| Benazepril Hcl | Benazepril Hcl | 51 | 13 |
| Estradiol | Estradiol | 51 | 25 |
| Fluconazole | Fluconazole | 51 | 33 |
| Methocarbamol | Methocarbamol | 51 | 19 |
| Spironolactone | Spironolactone | 51 | 17 |
| Diazepam | Diazepam | 50 | suppressed |
| Mupirocin | Mupirocin | 50 | 35 |
| Carvedilol | Carvedilol | 49 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 14 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 47 | 29 |
| Ibandronate Sodium | Ibandronate Sodium | 47 | 17 |
| Breo Ellipta | Fluticasone/Vilanterol | 46 | 12 |
| Promethazine Hcl | Promethazine Hcl | 46 | 14 |
| Alprazolam | Alprazolam | 45 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 43 | 12 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | 13 |
| Azithromycin | Azithromycin | 42 | 36 |
| Hydralazine Hcl | Hydralazine Hcl | 42 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 41 | 14 |
| Mounjaro | Tirzepatide | 41 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 14 |
| Pregabalin | Pregabalin | 39 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 39 | suppressed |
| Atenolol | Atenolol | 37 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 37 | suppressed |
| Irbesartan | Irbesartan | 36 | suppressed |
| Cephalexin | Cephalexin | 35 | 28 |
| Methenamine Hippurate | Methenamine Hippurate | 35 | 14 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 35 | suppressed |
| Trulicity | Dulaglutide | 35 | suppressed |
| Metformin Hcl | Metformin Hcl | 34 | 14 |
| Propranolol Hcl | Propranolol Hcl | 34 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 34 | suppressed |
| Gemtesa | Vibegron | 33 | suppressed |
| Memantine Hcl | Memantine Hcl | 33 | suppressed |
| Glipizide Er | Glipizide | 32 | 11 |
| Paroxetine Hcl | Paroxetine Hcl | 32 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 32 | suppressed |
| Januvia | Sitagliptin Phosphate | 31 | suppressed |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Rybelsus | Semaglutide | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 29 | 12 |
| Myrbetriq | Mirabegron | 29 | suppressed |
| Repatha Syringe | Evolocumab | 29 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 28 | 14 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 28 | 23 |
| Amoxicillin | Amoxicillin | 26 | 24 |
| Lovastatin | Lovastatin | 25 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 25 | suppressed |
| Vraylar | Cariprazine Hcl | 25 | suppressed |
| Clonazepam | Clonazepam | 24 | suppressed |
| Levoxyl | Levothyroxine Sodium | 24 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 14 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 23 | suppressed |
| Lactulose | Lactulose | 23 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 23 | suppressed |
| Lamotrigine | Lamotrigine | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 22 | suppressed |
| Acyclovir | Acyclovir | 21 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 19 |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 21 | 12 |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 20 | suppressed |
| Cefdinir | Cefdinir | 20 | 19 |
| Fenofibrate | Fenofibrate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 19 | suppressed |
| Ketoconazole | Ketoconazole | 19 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 19 | suppressed |
| Pilocarpine Hcl | Pilocarpine Hcl | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 18 | suppressed |
| Ibuprofen | Ibuprofen | 18 | suppressed |
| Primidone | Primidone | 18 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 17 | suppressed |
| Klor-Con M20 | Potassium Chloride | 17 | suppressed |
| Lorazepam | Lorazepam | 17 | 12 |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 17 | suppressed |
| Baclofen | Baclofen | 16 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Nitroglycerin | Nitroglycerin | 16 | 13 |
| Ramipril | Ramipril | 16 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 16 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 15 | suppressed |
| Lansoprazole | Lansoprazole | 15 | suppressed |
| Levemir Flexpen | Insulin Detemir | 15 | suppressed |
| Loperamide | Loperamide Hcl | 15 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 15 | suppressed |
| Xarelto | Rivaroxaban | 15 | suppressed |
| Finasteride | Finasteride | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Carisoprodol | Carisoprodol | 13 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 13 | suppressed |
| Naproxen | Naproxen | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Repatha Sureclick | Evolocumab | 13 | suppressed |
| Verapamil Er | Verapamil Hcl | 13 | suppressed |
| Clobetasol Emollient | Clobetasol Propionate/Emoll | 12 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 12 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Spironolactone-Hctz | Spironolact/Hydrochlorothiazid | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Halobetasol Propionate | Halobetasol Propionate | 11 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $759.43 · 48 records | ABBVIE INC. | AREXVY, Auvelity, CAPLYTA, CAPVAXIVE, ELIQUIS, EVENITY, FANAPT, GARDASIL 9, GEMTESA, GIVLAARI, Heplisav-B, JARDIANCE, Kerendia, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, SHINGRIX, TRELEGY ELLIPTA, UBRELVY, VAQTA, VAXNEUVANCE, VRAYLAR, Wegovy, XIFAXAN, ZAVZPRET, ZEPBOUND, ZORYVE, ZURZUVAE | 12 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error